Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab
Allergy and Asthma Proceedings · 2025
DOI: 10.2500/aap.2025.46.250026 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergy and Asthma Proceedings, 2025. Verfasst von Petra Staubach und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology and Allergy, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany. Hauptthemen laut MEDLINE: Quality of Life, Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Hereditary angioedema (HAE) is associated with substantial health-related quality of life (HRQoL) impairments. Complete disease control and life normalization are key treatment goals. In previous studies, garadacimab prevented HAE attacks with a favorable safety profile and HRQoL improvements.
Objective
HRQoL was evaluated in patients with HAE receiving garadacimab stratified by attack-free status.
Methods
In the pivotal phase III study (NCT04656418), 39 patients received garadacimab 200 mg subcutaneously once monthly and 25 volume-matched placebo. In the phase III open-label extension (OLE), 90 patients in the garadacimab-naive group (received placebo in previous studies or newly enrolled) and 71 patients in the previous garadacimab exposure group (received garadacimab in previous studies) received garadacimab (NCT04739059). Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status.
Results
In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free. In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20). In the phase III OLE study, the mean AE-QoL total score for patients who were garadacimab naive decreased from 46.2 (day 1) to 8.6 (month 12) for attack-free patients (n = 34) and from 54.5 to 23.5 for patients with one or more attacks (n = 30). For the previous garadacimab exposure group, AE-QoL improvements were maintained from previous studies, regardless of attack-free status.
Conclusion
Garadacimab was associated with HRQoL improvement versus run-in in all groups. After garadacimab exposure in previous studies, improvements were maintained in the phase III OLE study. Attack-free patients had the greatest HRQoL improvements, bringing them closer to complete disease control and life normalization.Clinical trials NCT04656418, NCT04739059, www.clinicaltrials.gov
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Dermatology and Allergy, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany.
- Allergy, Asthma and Immunology, Department of Medicine, Pediatrics, Obstetrics and Gynecology, Maternal-Fetal Medicine, and Biomedical Sciences, Pennsylvania State University, Hershey, Pennsylvania.
- Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
- Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic.
- CSL Behring, King of Prussia, Pennsylvania.
Zitieren
APA
Staubach, P., Craig, T. J., Fukuda, T., Aygoren-Pursun, E., Hakl, R., Braverman, J., Lawo, J. P., Pollen, M., Nenci, C., Li, P. H., & Farkas, H. (2025). Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab. Allergy and Asthma Proceedings. https://doi.org/10.2500/aap.2025.46.250026
Vancouver
Staubach P, Craig TJ, Fukuda T, Aygoren-Pursun E, Hakl R, Braverman J, et al. Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab. Allergy and Asthma Proceedings. 2025. doi:10.2500/aap.2025.46.250026
BibTeX
@article{Staubach2025,
author = {Staubach, Petra and Craig, Timothy J and Fukuda, Tomoo and Aygoren-Pursun, Emel and Hakl, Roman and Braverman, Julia and Lawo, John-Philip and Pollen, Maressa and Nenci, Chiara and Li, Philip H and Farkas, Henriette},
title = {Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab},
journal = {Allergy and Asthma Proceedings},
year = {2025},
doi = {10.2500/aap.2025.46.250026}
}
EUVIMED